Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Digital tech boosts hospital revenue

This article was originally published in The Gray Sheet

Executive Summary

"Digitally advanced hospitals tend to have reduced length of stay, increased quality of care and increased revenues," according to a March 7 PricewaterhouseCoopers report. Entitled "Reactive to Adaptive: Transforming Hospitals with Digital Technology," the report defines a digital hospital as having "a completely automated and deeply integrated set of health information services capabilities that fulfill clinical, financial, and administrative requirements." Medical devices, digital radiological image management solutions, and patient and equipment tracking solutions also compose core digital technologies. The report is based on an analysis by PWC and HIMSS Analytics of 36 hospitals considered to be digitally advanced; PWC also worked closely with the Indiana Heart Hospital...

Latest Headlines
See All
UsernamePublicRestriction

Register

MT021766

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel